Incidence of Candida Species Infections in a Military Hospital in Al-Kharj, Saudi Arabia

Nehad J. Ahmed1*

1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharij, Saudi Arabia.

Author’s contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

ABSTRACT

Aim: The present study aims to demonstrate the incidence of Candida species associated with infections in a Military hospital in Alkharij.

Methodology: This is a retrospective study that was conducted to assess the prevalence of Candida species in a Military hospital in Alkharij – Saudi Arabia. The isolates from various clinical specimens in 2018 and 2019 were studied.

Results: The percentage of candida species in the 2 years was 6.21% of isolates. The Candida albicans were 40.87% of the total Candida isolates. The majority of Candida species cultures were collected from wound/pus/skin or vagina and to lesser extent urine and lower respiratory tract.

Conclusion: Candida species are now common pathogens that cause infections specially in the gastrointestinal tract, vagina and at surgical site. It sometimes may lead to high morbidity and mortality rate. It is important to know the resistance rate for the fungi and it is important to start the implementation of antifungal treatment programs.

Keywords: Incidence; candida; fungal; infections.
1. INTRODUCTION

Over the last decades, *Candida* has emerged as one of the most important microorganisms causing nosocomial bloodstream infection in both adults and children worldwide [1–6]. *Candida* is a part of normal flora, and has more than 200 species, but only 10% of *Candida* species are known to cause human infections [7].

Bloodstream infections that were caused by *Candida* have drawn considerable attention in numerous medical fields over the previous decades because of their increasing incidence and high mortality rates [8-10].

Candidiasis and candidemia are among the most frequent health care infections resulting in high mortality and morbidity rate [11]. Candidiasis is occurring commonly in immunosuppressive patients and its epidemiology has changed over the previous decades [12].

It was reported that the nature of systemic *Candida* infections appeared to be changing continuously. Until recently, most of the infections were caused by *Candida albicans*. Nowadays, *Candida albicans* are becoming less common as other non-albicans *Candida* species begin to proliferate [13].

In the United States, *Candida* species are ranked as the fourth common group of microbes causing nosocomial bloodstream infections and account for 8% of all septicemias [14].

In Saudi Arabia, till now the incidence of candidemia isn’t accurately known. Previous studies revealed a low incidence rate in general ranging between 0.2 and 0.76 cases/1000 of hospital discharges [15–18], while more recent studies showed a higher incidence with a median rate of 1.65 per 1,000 of hospital discharges each year with a significant trend towards higher rates over time [19,20].

The present study aimed to demonstrate the incidence of *Candida* species infections in a Military hospital in Alkhair.

2. METHODOLOGY

This was a retrospective study conducted to assess the prevalence of *Candida* species in a military hospital in Alkhair – Saudi Arabia. The isolates from various clinical specimens in 2018 and 2019 were studied.

The study included all of the candida isolates that were collected in 2018 and 2019. All types of specimens were included such as urine cultures, vaginal cultures and other. The cultures before 2018 and after 2019 were excluded.

The cultures results were collected from Clinical Microbiology laboratory. The descriptive data were represented by frequencies of occurrence and percentages.

This study was approved by the IRB committee in the military hospital number 4101728.

3. RESULTS

In 2018, out of 827 total cultures (bacteria and fungi), there were 84 *Candida* cultures (10.16%). The majority of these cultures were collected from wound/pus/skin or vagina. Table 1 shows the types of specimen cultures in 2018.

| Types of tests             | Number | Percentage |
|---------------------------|--------|------------|
| Urine                     | 17     | 20.24      |
| Wound/pus/skin/vaginal    | 59     | 70.24      |
| Lower respiratory tissues | 8      | 9.52       |

The majority of the *Candida* cultures were collected from family medicine ward in 2018 (86.90%). The distribution of *Candida* species among different Departments in 2018 is shown in Table 2.

| Department             | Number | Percentage |
|------------------------|--------|------------|
| Medical ward           | 6      | 7.14       |
| Family ward            | 73     | 86.90      |
| Obstetrics             | 1      | 1.19       |
| Intensive care unit    | 2      | 2.38       |
| Isolation              | 2      | 2.38       |
In 2019, out of 1023 total cultures (bacteria and fungi) there were 31 Candida cultures (3.03%). Most of the collected Candida species cultures were collected from wound/pus/skin or vaginal (64.52%). Table 3 shows the types of specimen tested in 2019.

| Types of test | Number | Percentage |
|---------------|--------|------------|
| Urine         | 11     | 35.48      |
| Wound/pus/skin| 20     | 64.52      |

Candida cultures in 2019 were mainly collected from Accident and Emergency Department (67.74%). The distribution of Candida species among different department in 2019 is shown in Table 4.

| Department       | Number | Percentage |
|------------------|--------|------------|
| Family ward      | 4      | 12.90      |
| Obstetric        | 6      | 19.35      |
| Accident and     | 21     | 67.74      |
| Emergency        |        |            |

As a total the percentage of Candida species in the 2 years was 6.21% (out of 1850 isolates, there were 115 Candida isolates).

4. DISCUSSION

In 2018, Candida is the fourth most common isolated microbes in the Military hospital. Previous studies found that in hospitalized patients and especially in the critically ill patients, Candida is between the fourth and sixth most common isolated pathogen in bloodstream infections [21–25]. Similarly, these studies reported that Candida isolates were common but in contrast of the present study, there isolates were from bloodstream but in the present study the isolates in 2018 were from urine, wound, skin, pus, vaginal or lower respiratory. Moreover, in the present study in 2019, Candida was the seventh most common isolated microbes in the Military hospital and the Candida isolates were collected from urine, wound, skin, pus or vaginal. Sheevani et al. stated that Candida albicans is the sixth cause of most common nosocomial infections [26]. In a university hospital, Candida isolates cause 14.13% of the infections specially Candida albicans [27].

Unfortunately, in the present study the incidence of different Candida species was not found and the collected results were divided to Candida albicans and other types of Candida. In 2018, 21 out of 84 (25.00%) Candida species isolated were for Candida albicans. But in 2019, 26 out of 31 (83.87%) Candida isolates were for Candida albicans. Therefore, the Candida albicans in the 2 years were 40.87% of the total Candida isolates.

It was reported that reported that Candida tropicalis was the most common agent, followed by C. albicans, C. parapsilosis, C. glabrata, C. mesorugosa, and C. krusei [28]. Furthermore, it was reported that Candida albicans remains the predominant cause of invasive candidiasis, accounting for over half of all cases followed by Candida glabrata which has emerged as the second most common cause of invasive candidiasis in the United States [29].

The nature of systemic Candida infections appears to be changing. Until recently, the majority of infections were caused by Candida albicans, but nowadays this species is becoming less common and other Candida species begin to proliferate, particularly in certain types of patients [13].

The majority of the Candida isolates were collected from wounds, skin and vagina. This is rational because Candida species commonly lead to infections in vagina and surgical sites. Similarly, it was reported that Vulvovaginal Candidiasis refers to vaginal and vulval symptoms caused by a yeast, most often Candida albicans. It affects 75% of women on at least one occasion over a lifetime [30]. Moreover, vaginal candidiasis in the United States is the second most common type of vaginal infection after bacterial vaginal infections [31]. Furthermore, it was reported that an estimated 1.4 million outpatient visits for vaginal candidiasis occur annually in the United States [32]. Candida species commonly cause both early and late postoperative infections [33].

Furthermore, there were some isolates collected from urine (24.35%) and lower respiratory tract (6.96%) that may indicate an invasive candidiasis and usually occurred in immune compromised patients. According to CDC, candidiasis occurs commonly in the mouth or throat and in the vagina. CDC reported that invasive candidiasis occurs when Candida species enter the bloodstream or affect internal organs like the kidney, heart, or brain [34].
The risk factors for acquisition of *Candida* in the respiratory tract include use of mechanical ventilation, exposure to antibiotics, immune compromised status, hospital or intensive care unit stay and critical illness [35]. Reports by Fisher et al. indicated that infection of the urinary tract due to *Candida albicans* is uncommon [36]. Reports by Kauffman indicated that *Candida* species appear to be unique in their ability to both colonize and cause invasive disease in the urinary tract [37].

### 5. CONCLUSION

*Candida* species are now common pathogens that cause infections specially in the gastrointestinal tract, vagina and surgical sites. They also cause invasive infections in immune compromised patients and may lead to high morbidity and mortality rates in these patients. The present study shows that *Candida* associated infections were common. In the past, the majority of *Candida* associated infections were caused by *Candida albicans* but nowadays there is an increase in the incidence of infections that are caused by other *Candida* species. It is important to know the resistance rate for *Candida* species and it is important to start the implementation of antifungal treatment programs.

### CONSENT

As per international standard or university standard written patient consent has been collected and preserved by the author.

### ETHICAL APPROVAL

It is not applicable.

### ACKNOWLEDGEMENT

This Publication was supported by the Deanship of Scientific Research at Prince Sattam bin Abdulaziz University.

### COMPETING INTERESTS

Author has declared that no competing interests exist.

### REFERENCES

1. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O et al. Epidemiology of candidaemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 2004; 23(4):317–322.
2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis. 2005;41(9):1232-9.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309-17.
4. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ et al. International surveillance of bloodstream infections due to *Candida* species: Frequency of occurrence and *in vitro* susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J ClinMicrobiol. 2001;39(9):3254-9.
5. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J. Epidemiology of candidemia in Swiss tertiary care hospitals: Secular trends, 1991–2000. Clin Infect Dis. 2004;38(3):311-20.
6. Almoosa Z, Ahmed GY, Omran A, AlSarheed A, Alturki A, Alaqeel A. Invasive candidiasis in pediatric patients at King Fahad Medical City in Central Saudi Arabia. A 5-year retrospective study. Saudi Med J. 2017;38(11):1118-1124.
7. Cohen R, Roth FJ, Delgado E, Ahearn DG, Kalser MH. Fungal flora of the normal human small and large intestine. N Engl J Med. 1969;280(12):638-41.
8. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess of stay. Arch Intern Med. 1988;148:2642-5.
9. Wenzel RP. Nosocomial candidemia: Risk factors and attributable mortality. Clin Infect Dis. 1995;20:1531-4.
10. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S et al. Attributable mortality of nosocomial candidemia. Clin Infect Dis. 2003;37:1172-7.
11. Lockhart SR. Current epidemiology of *Candida* Infection. Clin. Microbiol. Newsl. 2014;36(17):131–136.
12. Yapar N. Epidemiology and risk factors for invasive candidiasis. TherClin Risk Manag. 2014;10:95-105.
13. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004;23(4):317-22.
14. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. 1999;33:121-129.
15. Al-Tawfiq JA. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996–2004. Int J Infect Dis. 200;11(3):239-44.
16. Bukhari HA. Nosocomial candidemia in a tertiary care hospital in Saudi Arabia. Mycopathologia. 2002;153(4):195–198.
17. Akbar DH, Tahawi AT. Candiemia at a University Hospital: Epidemiology, risk factors and predictors of mortality. Ann. Saudi Med. 2001;21(3-4):178–182.
18. Al-Hedailhy SS. The yeast species causing fungemia at a university hospital in Riyadh, Saudi Arabia, during a 10-year period. Mycoses. 2003;46(8):293–298.
19. Al Thaqafi AHO, Farahat FM, Al Harbi MI, Al Amri AFW, Perfect JR. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia. International Journal of Infectious Diseases. 2014;21:5–9.
20. Omrani AS, Makkawy EA, Baig K, Barethwian AA, Almuthree SA, Elkhizzi NA et al. Ten-year review of invasive Candida infections in a tertiary care center in Saudi Arabia. Saudi Med J. 2014;35(8):821-6.
21. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008;32(Suppl 2):S87-91.
22. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immuno suppressed patients. Lancet Infect Dis. 2003;3(11):685-702.
23. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med. 2006;34(3):857-63.
24. Al-Dorzi HM, Sakkijha H, Khan R, Aldabbagh T, Toledo A, Nitnika P et al. Invasive candidiasis in critically ill patients: A prospective cohort study in two tertiary care centers. J Intensive Care Med. 2018;88506618767835.
25. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med. 2002;113(6):480-5.
26. Sheevani, Sharma P, Aggarwal A. Nosocomial Candida infection in a rural tertiary care hospital. J Clin Diagn Res. 2013;7:405–6.
27. Ahmed NJ, Khan MF. Antibiotic Resistance Patterns in a University Hospital in Al-Kharj City. Antibiotic Resistance Patterns in a University Hospital in Al-Kharj City. J. Pharm. Res. Int. 2019;31(5):1-5.
28. Bac ND, Anh LT, Quang LB, Luc NK, Nga TTT, Nagi M et al. Prevalence of Candida bloodstream isolates from patients in two hospitals in Vietnam. Iran J Microbiol. 2019;11(2):108-113.
29. Pfaller MA, Diekema DJ. Epidemiology of Invasive Candidiasis: A Persistent Public Health Problem. ClinMicrobiol Rev. 2007;20(1):133-63.
30. DermNet NZ. Vulvovaginal candidiasis; 2020. [cited 31 March 2020]. Available:https://dermnetnz.org/topics/vulvovaginal-candidiasis/
31. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961-71.
32. Benedict K, Jackson BR, Chiller T, Beer KD. Estimation of direct healthcare costs of fungal diseases in the United States. Clin Infect Dis. 2019;68(11):1791-1797.
33. ASHP. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery; 2020. [cited 31 March 2020]. Available:https://www.ashp.org/media/assets/policy-guidelines/docs/therapeutic-guidelines/therapeutic-guidelines-antimicrobial-prophylaxis-surgery.ashx
34. CDC. Candidiasis; 2020. [cited 31 March 2020] Available:https://www.cdc.gov/fungal/diseases/candidiasis/index.html
35. Pendleton KM, Huffnagle GB, Dickson RP. The significance of Candida in the human respiratory tract: our evolving understanding. Pathog Dis. 2017;75(3).

36. Fisher JF, Chew WH, Shadomy S, Duma RJ, Mayhall CG, House WC. Urinary tract infections due to Candida albicans. Rev Infect Dis. 1982;4(6):1107-18.

37. Carol A. Kauffman. Diagnosis and Management of Fungal Urinary Tract Infection. Infect Dis Clin North Am. 2014;28(1):61-74.